Meronem Iv (Meropenem Anhydrous)

Meropenem belongs to the carbapenem class and works by binding to penicillin‑binding proteins on bacterial cell walls. This inhibits the final step of peptidoglycan cross‑linking, weakening the wall and causing bacterial cell lysis and death. Its structure resists most β‑lactamases, giving activity against many resistant organisms.

The dosage of Meronem Iv is individualized by the prescribing clinician based on infection type, severity, patient weight, renal function and local susceptibility patterns. Dosing regimens are not standardized in this description; prescribers determine the appropriate amount and infusion schedule for each patient.

Safety data for meropenem in pregnancy are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult a healthcare professional, as the drug may be excreted in breast milk.

To order Meronem Iv, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Meropenem and imipenem are both carbapenems with broad‑spectrum activity, but meropenem is generally considered to have a slightly broader Gram‑negative coverage and a lower risk of seizures. Imipenem is often co‑formulated with cilastatin to reduce renal metabolism. Choice between them depends on local resistance patterns, patient renal function and safety considerations.

Meronem Iv must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. Once reconstituted, use the preparation within the time frame specified in the product labeling and maintain cold‑chain conditions during transport.

Meronem Iv is given by intravenous infusion. The reconstituted solution is diluted in an appropriate compatible IV fluid and infused over a period recommended by the prescriber, typically 15‑30 minutes. Administration should follow aseptic technique and be performed by qualified healthcare personnel in a clinical setting.

Serious adverse events include seizures, especially in patients with underlying central nervous system disorders or renal impairment, and severe hypersensitivity reactions such as anaphylaxis. Clinicians should also be vigilant for Clostridioides difficile‑associated colitis, acute renal failure, and profound neutropenia, all of which require immediate medical attention.

Meronem Iv is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is advised for patients with a history of seizures, severe renal impairment, or documented β‑lactam allergy. In such cases, alternative antimicrobial therapy should be considered.